BRPI1010024A2 - derivados de aminopirrolidinona e uso dos mesmos - Google Patents

derivados de aminopirrolidinona e uso dos mesmos

Info

Publication number
BRPI1010024A2
BRPI1010024A2 BRPI1010024A BRPI1010024A BRPI1010024A2 BR PI1010024 A2 BRPI1010024 A2 BR PI1010024A2 BR PI1010024 A BRPI1010024 A BR PI1010024A BR PI1010024 A BRPI1010024 A BR PI1010024A BR PI1010024 A2 BRPI1010024 A2 BR PI1010024A2
Authority
BR
Brazil
Prior art keywords
aminopyrrolidinone
derivatives
aminopyrrolidinone derivatives
Prior art date
Application number
BRPI1010024A
Other languages
English (en)
Inventor
E Duggan Mark
Original Assignee
Link Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Link Medicine Corp filed Critical Link Medicine Corp
Publication of BRPI1010024A2 publication Critical patent/BRPI1010024A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1010024A 2009-06-05 2010-06-07 derivados de aminopirrolidinona e uso dos mesmos BRPI1010024A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18438609P 2009-06-05 2009-06-05
US29502310P 2010-01-14 2010-01-14
PCT/US2010/037582 WO2010141932A1 (en) 2009-06-05 2010-06-07 Aminopyrrolidinone derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BRPI1010024A2 true BRPI1010024A2 (pt) 2019-09-24

Family

ID=42635266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010024A BRPI1010024A2 (pt) 2009-06-05 2010-06-07 derivados de aminopirrolidinona e uso dos mesmos

Country Status (12)

Country Link
US (2) US8252829B2 (pt)
EP (1) EP2438059A1 (pt)
JP (1) JP2012529432A (pt)
CN (1) CN102548986A (pt)
AU (1) AU2010256360A1 (pt)
BR (1) BRPI1010024A2 (pt)
CA (1) CA2764387A1 (pt)
IL (1) IL216768A0 (pt)
MX (1) MX2011013016A (pt)
SG (1) SG176628A1 (pt)
WO (1) WO2010141932A1 (pt)
ZA (1) ZA201109034B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2211911A4 (en) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc METHOD FOR DIAGNOSIS AND MONITORING OF THE TREATMENT OF LEWY BODILY DAMAGE BY EVALUATING THE DOPAMIN TRANSPORTER MIRROR
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
BR112014024672A8 (pt) * 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
EP4124346A3 (en) * 2012-06-19 2023-04-19 University of Florida Research Foundation, Inc. Compositions and methods for treating diseases
US8818117B2 (en) * 2012-07-19 2014-08-26 Sony Corporation Method and apparatus for compressing Z-stack microscopy images
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (zh) 2012-10-09 2015-06-10 宝洁公司 鉴定协同化妆品组合的方法
CN104271144B (zh) 2012-12-13 2018-06-26 新田明胶株式会社 成肌细胞分化促进剂
US10906981B2 (en) * 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
ES2885551T3 (es) * 2014-12-15 2021-12-14 Univ California Agentes antiarrítmicos
JP6746945B2 (ja) * 2015-06-30 2020-08-26 ソニー株式会社 情報処理装置、情報処理システム及び情報処理方法
US10407023B2 (en) * 2017-01-30 2019-09-10 Ford Global Technologies, Llc Remote starting of engines via vehicle keypads
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
CN112945913A (zh) * 2019-12-10 2021-06-11 中国科学院大连化学物理研究所 一种萘酰亚胺类荧光探针在脂滴成像领域中的应用
CN116354923B (zh) * 2021-12-27 2025-05-09 江苏恩华药业股份有限公司 一种含氮杂环化合物及其应用
CN120189907B (zh) * 2025-05-26 2025-08-08 上海交通大学 一种深度除磷材料及其制备方法和应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5025001A (en) 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5130330A (en) 1990-01-31 1992-07-14 G. D. Searle & Co. Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for cns disorders
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
AU658441B2 (en) 1991-07-23 1995-04-13 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
GB2267966A (en) 1992-06-17 1993-12-22 Merck & Co Inc A fluorescence assay for farnesyl protein transferase activity
HUT77888A (hu) 1994-12-13 1998-09-28 Corvas International, Inc. Enzim inhibitor hatású aromás heterociklusos származékok
AU5772396A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6001835A (en) 1996-04-03 1999-12-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891360A4 (en) 1996-04-03 2002-05-15 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
JPH10215175A (ja) 1996-11-29 1998-08-11 Sony Corp Pll回路及び信号再生装置
CA2275796A1 (en) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2293713C (en) 1997-06-17 2006-12-05 Schering Corporation Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
US5972898A (en) 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6335343B1 (en) 1999-03-03 2002-01-01 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001005780A1 (en) 1999-07-16 2001-01-25 Sankyo Company, Limited Coumarone analogues
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
WO2001017992A1 (en) * 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6441017B1 (en) 1999-09-09 2002-08-27 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ATE314362T1 (de) 1999-10-12 2006-01-15 Takeda Pharmaceutical Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2002275064A (ja) 2001-01-15 2002-09-25 Sankyo Co Ltd クロマン類縁体を含有する医薬
AU2002303264A1 (en) 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
CA2471566A1 (en) 2002-01-10 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的噁二唑
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
RU2357962C2 (ru) 2002-09-06 2009-06-10 Элан Фармасьютикалз, Инк. Пролекарственные производные 1,3-диамино-2-гидроксипропана
JPWO2004026873A1 (ja) 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤
WO2004037817A1 (ja) 2002-10-25 2004-05-06 Mitsubishi Pharma Corporation N−オキシド化合物
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
EP1656931A1 (en) * 2004-11-15 2006-05-17 Exonhit Therapeutics SA Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
WO2006063010A2 (en) 2004-12-08 2006-06-15 Nuada, Llc Compounds and methods of use thereof
WO2006074262A1 (en) 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7511077B2 (en) 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
EP1864971A4 (en) 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007029121A2 (en) 2005-07-21 2007-03-15 Galderma Research & Development Novel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions
BRPI0614502A2 (pt) 2005-07-30 2011-03-29 Astrazeneca Ab Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
EP1883634A2 (en) 2005-09-13 2008-02-06 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for preparing simvastatin and intermediates thereof
US20070129437A1 (en) 2005-12-06 2007-06-07 Ferenc Korodi Process for preparing simvastatin and intermediates thereof
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
BRPI0619733A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
EP1991544B1 (en) 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
US8022214B2 (en) 2007-01-24 2011-09-20 Polyera Corporation Organic semiconductor materials and precursors thereof
GB0707051D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
EP2147310A4 (en) 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
US8772312B2 (en) 2007-10-10 2014-07-08 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Heterocyclic compounds as CRTH2 receptor antagonists
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2268636A1 (en) 2007-12-11 2011-01-05 Schering Corporation Gamma secretase modulators
TWI447099B (zh) 2008-01-29 2014-08-01 Nissan Chemical Ind Ltd Aryl sulfonic acid compounds and the use of electron acceptables
KR101331032B1 (ko) 2008-07-30 2013-11-19 삼성전자주식회사 가상화 환경과 결합된 어플리케이션 실행 방법
EP2237405B1 (en) 2009-03-31 2013-02-20 STMicroelectronics Srl Control device for the change of the driving modality of an electromagnetic load
US8473905B1 (en) 2009-09-30 2013-06-25 Emc Corporation Managing user interface characteristics in displaying data storage systems information
JP5646195B2 (ja) 2010-03-30 2014-12-24 富士フイルム株式会社 インクジェット記録装置及び断熱処理方法
TWI437908B (zh) 2011-05-17 2014-05-11 Leadtrend Tech Corp 具電流平衡功能的驅動電路
JP7663083B2 (ja) 2022-03-14 2025-04-16 株式会社デンソー 画像処理装置

Also Published As

Publication number Publication date
EP2438059A1 (en) 2012-04-11
US8252829B2 (en) 2012-08-28
WO2010141932A1 (en) 2010-12-09
CN102548986A (zh) 2012-07-04
US20130289086A1 (en) 2013-10-31
AU2010256360A1 (en) 2012-01-12
MX2011013016A (es) 2012-04-20
ZA201109034B (en) 2013-02-27
SG176628A1 (en) 2012-01-30
CA2764387A1 (en) 2010-12-09
US20110021590A1 (en) 2011-01-27
IL216768A0 (en) 2012-02-29
JP2012529432A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BR112014014763A8 (pt) novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BR112012006404A2 (pt) derivados de di-hidropteridinona, processo de preparação e uso farmacêutico dos mesmos
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
CR20130360A (es) Compuesto heterocíclico y su uso
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.